Nasal cavity and paranasal sinus squamous cell carcinoma

Summary

Nasal cavity and paranasal sinus squamous cell carcinoma (MONDO:0044787) is a cancer and 9 clinical trials. Top therapeutic interventions include cisplatin, temsirolimus, and cediranib maleate. A subtype of head and neck squamous cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	nasal cavity and paranasal sinus squamous cell carcinoma
Mondo ID	MONDO:0044787
NCIT	C68611
UMLS	C0280332
MedGen	124722
GARD	0025910
Is cancer (heuristic)	yes

Also known as: nasal cavity and paranasal sinus squamous cell cancer · nasal cavity and paranasal sinus squamous cell carcinoma

Disease family

This is a subtype of head and neck squamous cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › head and neck squamous cell carcinoma › nasal cavity and paranasal sinus squamous cell carcinoma

Related subtypes (12): pharyngeal squamous cell carcinoma, cornea squamous cell carcinoma, lacrimal gland squamous cell carcinoma, external ear squamous cell carcinoma, laryngeal squamous cell carcinoma, nasal cavity squamous cell carcinoma, nasopharyngeal squamous cell carcinoma, conjunctival squamous cell carcinoma, middle ear squamous cell carcinoma, primary intraosseous squamous cell carcinoma, paranasal sinus squamous cell carcinoma, lip and oral cavity squamous cell carcinoma

Subtypes (1): non-keratinizing sinonasal squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	6
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00707473	PHASE2	ACTIVE_NOT_RECRUITING	Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
NCT03493425	PHASE2	RECRUITING	Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
NCT00458978	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT01256385	PHASE2	COMPLETED	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
NCT02196168	PHASE2	TERMINATED	Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT02538510	PHASE1/PHASE2	COMPLETED	Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
NCT03422536	PHASE2	COMPLETED	Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT01254617	PHASE1	COMPLETED	Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
NCT02388932	Not specified	TERMINATED	Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	3
TEMSIROLIMUS	4	1
CEDIRANIB MALEATE	3	1
FICLATUZUMAB	3	1